December 1, 2022

BCAN

 

BYND Cannasoft Enterprises Inc. and SmallCapVoice.com, Inc.

_______

OUR NEW PROFILE IS:   (Nasdaq: BCAN)

YAHOO FINANCE Has the Entire Float Under 880K!!

The EZ-G device represented a $28 million transaction

Tel Aviv Listed Together Pharma’s Subsidiary Globus Pharma Ltd and BYND Cannasoft Enterprises’ Subsidiary Sign First Commercial Agreement for Medical Cannabis Products

 

_____________________ Hello Everyone, We plan on sending an update this weekend regarding our most recent profiles. We have another company that we want you to put on your radar as we head towards the weekend. Pull up BCAN immediately.  This is a brand new company that we have never profiled before on our site. BYND Cannasoft Enterprises Inc. owns and markets a proprietary customer relationship management (CRM) software product, known as “Benefit CRM.” BYND’s Benefit CRM software enables small and medium‐sized businesses to optimize their day‐to‐day business activities such as sales management, personnel management, marketing, call center activities and asset management. The company’s next-generation Benefit CRM platform is now ready for BETA testing. Building on its 20 years of experience in CRM software, BYND Cannasoft Enterprises Inc. has recently begun development of an innovative new CRM platform, designed specifically to serve the needs of the medical cann-a-bis industry. This new platform will be the first of its kind for the medical cann-a-bis field and the Company is confident it will transform the industry into a more organized, accessible, and price transparent market. Data and information collected through the operation of the Cann-a-bis Farm and the products it produces will allow BYND to test its new Cann-a-bis CRM platform and adjust the platform as necessary. Additionally, operating the Cann-a-bis Farm and selling medical cann-a-bis will bring in additional revenue to further support BYND during the initial roll‐out years of its cann-a-bis CRM platform. BYND Cannasoft Enterprises Inc.’s CRM and ERP system is a state-of-the-art CRM designed with years of industry and market specific experience. In its second generation, BYND Cannasoft Enterprises Inc. wishes to build tailored software for the cann-a-bis industry. The CRM and ERP system will be integrated into the company’s delivery and recommendation system to help manage inventory, create performance reports and financial reports.

 

*****BREAKING NEWS MINUTES AGO*****

Tel Aviv Listed Together Pharma’s Subsidiary Globus Pharma Ltd and BYND Cannasoft Enterprises’ Subsidiary Sign First Commercial Agreement for Medical Cannabis Products

VANCOUVER, British Columbia and ASHKELON, Israel, Oct. 27, 2022 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) announced today its Israeli subsidiary signed an agreement with Globus Pharma LTD, a subsidiary of Israeli-based Together Pharma Ltd (TA: TGTR), for the cultivation, production, and distribution of medical cannabis products that are expected to generate significant revenues for the company before costs of manufacturing and distribution fees. The manufacturing of the medical cannabis products will adhere to BYND Cannasoft’s instructions and stringent standards. These products will be exclusively marketed and distributed by BYND Cannasoft in Israel through Globus Pharma. Due to their safety profile and strong therapeutic efficacy, the products are based on strains developed by Together Pharma and selected exclusively by BYND Cannasoft.

BYND Cannasoft’s agreement with Together Pharma will take effect upon the issuance of a full license by the Medical Cannabis Unit at the Ministry of Health of the State of Israel (the “MCU”). While BYND Cannasoft has received initial approval from the MCU to engage in medical cannabis without direct contact with the substance, there is no guarantee that it will receive a full license.

Israel has emerged as one of the leading countries for the consumption of medical cannabis in the world. According to Israel’s Health Ministry, more than 100,000 Israeli citizens have medical cannabis permits, a 1,600 percent increase over the past decade. Regulations governing the research, cultivation, processing, distribution, and sale of cannabis remain extremely strict. Israel’s Health Ministry estimated that medical cannabis consumption increased to 43 metric tons in 2021, from 28.5 million in 2020. According to Prohibition Partners, an industry analysis firm, Israel’s medicinal cannabis market had an approximate value of $264 million in 2021, roughly $7 million less than all of Europe’s.

Yftah Ben Yaackov, CEO and Director of BYND, said, “The medical cannabis arena is being commercialized rapidly in Israel, and we expect to see more development in Israel and worldwide. Many of today’s decision-makers in the pharmaceutical industry and the medical community understand the benefits produced by specific cannabis strains.” Mr. Yaackov continued, “The products BYND Cannasoft plans to bring to market may provide additional treatment options and respond to the unmet medical needs of patients. After an in-depth and lengthy review, we partnered with Together Pharma because we knew we could have a tremendous impact on the community. The high-quality medical cannabis Together Pharma produces in accordance with BYND Cannasoft’s high quality and safety standards – will help us realize our goal of improving patients’ lives.”

 

 

This system gives the growers a deep insight into all aspects of managing a cann-a-bis farm and cann-a-bis distribution from the amounts of fertilizer right to managing delivery revenue – all with a few clicks. The company’s powerful BI tools allow growers to receive information in real-time, in great resolution to allow optimal efficiency and profit. The Company’s plans include the construction of 4 state of the art greenhouses, housing approximately 2.5 acres of total growing area. BYND Cannasoft Enterprises Inc. estimates that once fully operational, its Cann-a-bis farm facility will be able to produce 7,500kg of raw cann-a-bis each year. BYND also intends to work with strategic partners to develop and market new, proprietary cann-a-bis infused products for sale throughout Israel and for export. The company operates on 3 parallel levels as part of its plans to enter the market for growing and selling medical cann-a-bis:

  1. The company is working to transfer the initial permit for the cultivation and multiplication of medical cann-a-bis according to the partnership agreement with the Bzizinsky family, after its transfer, the company will operate for the planning and construction of a growing facility in Moshav Kochav Michael.
  2. The company has completed the planning and placement of an internal breeding facility and has applied for a growing and breeding license for this facility.
  3. The company has submitted an application for a license to trade in medical cann-a-bis “without contact with the substance” known as a constructive license, after receiving it the company will be able to implement agreements it has signed with various growers for marketing and sales of the company’s private label.

BCAN broke the news in September that they have signed a share purchase agreement to acquire 100% ownership of Zigi Carmel Initiatives & Investments Ltd. (ZC) which holds the patent pending intellectual property for the EZ-G device. Under the terms of the share purchase agreement, BCAN will issue to ZC’s owner 7,920,000 common shares and pay $100K to cover legal expenses. The EZ-G device represented a $28 million transaction that Ben Yaackov says will add value to BYND as it seeks regulatory approval and patent registration. The EZ-G device uses proprietary software (provisional application) to regulate the flow of low-concentration CBD oils into the soft tissues of the female reproductive system to treat candida, dryness, scars and other health issues. “This, together with our great development in the software field and the preparations of obtaining the license to practice medical cannabis, makes the last two years a period of great prosperity and success,” he adds. “We are confident that it will bring significant value for the Company in the upcoming year.” Wrapping up 2022 and moving into 2023, Ben Yaackov says he expects to see continued progress in the Company’s software development and sales expansion. Additionally, BYND is in the final stage of obtaining a license to engage in the sale of medical cannabis without connecting with the substance. “This is a special license that few have in Israel. It allows you to establish products in the medical cannabis field, a label of your own, through an existing grower that has the license to grow medical cannabis in Israel,” he explains. “That will bring us another revenue from the side of selling medical cannabis products, and above all that, I believe that we will significantly advance the new project and finish the patent registration and put other necessary regulations and build a prototype until the end of the fourth quarter of 2023.”

CLIENTS

 

BYND Cannasoft Enterprises Inc. Signs Agreement for the Acquisition of Israeli-Based Zigi Carmel Initiatives & Investments Ltd. In a Share Swap Agreement Valued at US $28Mn

VANCOUVER, British Columbia, Sept. 18, 2022 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) (CSE: BYND) (“BYND” or the “Company”) announced today that it has signed a share purchase agreement to acquire 100% ownership of Zigi Carmel Initiatives & Investments Ltd. (“ZC”) which holds the patent pending intellectual property for a therapeutic device (the “EZ-G device”) that uses low concentrations of CB oils, such as hemp seed oil and other natural oils, to treat certain women’s health issues… The EZ-G device is a unique, patent-pending device that, combined with proprietary software (provisional application), regulates the flow of low-concentration CB oils into the soft tissues of the female reproductive system. According to research conducted across the globe, treatment with low-concentration CB oils can relieve candida, dryness, scars, and many other female health issues. BYND intends to pursue the final registration of the patent and establish a marketing and sales system for the EZ-G device.The Company’s ‘Go to Market’ strategic plan is based on combined B2B and B2C sales. Numerous studies have shown CB interacts with the endocann-a-binoid system, a master regulatory system with receptors all around the body. By activating these receptors, CB can have health benefits that help make sex more approachable and pleasurable by reducing stress, enhancing one’s mood, promoting body comfort, and treating vaginal issues. According to the Brightfield Group, a cann-a-bis industry data research firm, sales of CB products could reach $11Bn by 2027. A recent Zion Market Research study indicates the market size of global gynecology devices was worth $10.8Bn in 2021 and is estimated to exceed $19.5Bn by 2028 with a compound annual growth rate (CAGR) of approximately 10.3 percent. … Yftah Ben Yaackov, CEO and a Director of BYND, said, “From the moment we complete the purchase of ZC, we plan to hit the ground running by initially securing any required regulatory approval from the appropriate authorities. We will continue to pursue the registration of the patent, which contains over 100 claims, prototype production and start validation tests, and contract with suppliers for the production of the device and the oils used in the EZ-G device. The demand for a unique device combined with software, such as the EZ-G device, stems from the increasing occurrence of chronic conditions and the rising adoption of self-health management. Using a device at home is a very cost-effective treatment, and it opens up a vast channel for millions of women.” Mr. Ben Yaackov continued, “We hope to use the knowledge we have gained in the medical cann-a-bis field to significantly improve the quality of life of women suffering from symptoms such as those mentioned above.

BYND Cannasoft Enterprises Inc. Launches Beta Test for Managing Farms CRM Platform at Israel’s Weizmann Institute of Science

VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) (CSE: BYND) (“BYND” or the “Company”) announced that its subsidiary BYND – Beyond Solutions Ltd. has signed an agreement with the Weizmann Institute of Science for the use of its proprietary software. … Yftah Ben Yaackov, CEO and a Director of BYND, said, “This is an extremely important step in the development of BYND Cannasoft Enterprises medical cann-a-bis software since the Weizmann Institute has many greenhouses of various types that can cover all the development possibilities of the software in the coming year…

MANAGEMENT

Moti Maram

President and Director

In 1986, together with a partner company, he founded a computer company that mainly provided services to EXATEC-compliant IBM AS 400 computers and subsequently sales and service to the first PCs in the world. After identifying a need for CRM and ERP software, Maram and his partner, Avner Tal, established a software company that manufactures CRM and ERP management software called BENEFIT in 2000.

Harold Wolkin

Harold is a retired, former Investment Banker and Financial Analyst with over 40 years of business experience. An advisor to Chief Executive Officers and Board of Directors of both public and private companies. Strong financial expertise, a Chartered Financial Analyst (CFA) and member of the Institute of Corporate Directors.

Yftah Ben Yaackov

CEO and Director

Professional lawyer since 2004. Specialized in real estate related issues on all aspects of it including real estate corporations, complex sales transactions, real estate unions, real estate taxation. Notary License holder since 2014. Managed large projects of tens of thousands Square meters for a total amount of above 400 million NIS. At the last 5 years yftah has assembled the business activity of 2 of the largest medical cannabis company’s in Israel and has an enormous experience and knowledge in this field.

Dr. Stefánia Szabó

Director

Stefánia is the Vice President of Pace Law Firm and Director of International Relations at Pace Global Advantage in Toronto, Canada. She is a former diplomat, a charismatic government services, management and public relations professional with 25 years of progressive experience. She is an international lawyer by profession, and serves as member of the executive committee of the Canada-Israel Chamber of Commerce.

Avner Tal

VP Sales & Marketing, CTO and Director

 

Technology director of Beyond Solution Company. I studied electronics and control. I served in the Navy and I was in the team that implemented and developed the technology and even carried out the experiments that included “smart” missiles. Joined Moti to established a computer company that supported Exatech computers and its innovative network.

NEWS

Sincerely,

DISCLAIMER

The Viral Stocks Team DISCLAIMER THIS WEBSITE/NEWSLETTER IS A WHOLLY OWNED SUBSIDIARY OF GLOBAL COIN MEDIA, LLC. HEREIN REFERRED TO AS GCM, LLC. WE ARE A NEVADA COMPANY. OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF THIRTY THOUSAND USD FOR 1 ONE DAY BSGM AWARENESS CAMPAIGNS BY A THIRD PARTY, NORTH EQUITIES CORP. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: GCMLLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD GCM, LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. GCMLLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND GCM, LLCMAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD GCM, LLC. STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.GCM, LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. GCM, LLCDOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND GCM, LLCFURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS.IN PREPARING THIS PUBLICATION,GCM, LLCHAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, GCM, LLCAND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. GCM, LLCIS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS GCM, LLCRESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. GCM, LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.